Immunomedics Inc. (NASDAQ:IMMU) shares rose 2.5% on Thursday . The stock traded as high as $2.87 and last traded at $2.83, with a volume of 272,832 shares changing hands. The stock had previously closed at $2.76.

IMMU has been the subject of several recent research reports. Jefferies Group upgraded Immunomedics from a “hold” rating to a “buy” rating and lifted their price target for the company from $1.50 to $5.00 in a research report on Friday, May 6th. They noted that the move was a valuation call. Wells Fargo & Co. reiterated a “buy” rating on shares of Immunomedics in a research report on Tuesday, May 24th. Finally, Zacks Investment Research upgraded Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th.

The firm’s market cap is $260.76 million. The company’s 50 day moving average is $2.68 and its 200 day moving average is $2.90.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.06. On average, equities research analysts anticipate that Immunomedics Inc. will post ($0.47) EPS for the current year.

In other news, CEO Cynthia L. Goldenberg sold 63,959 shares of the company’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $4.09, for a total transaction of $261,592.31. Following the completion of the transaction, the chief executive officer now directly owns 703,029 shares of the company’s stock, valued at approximately $2,875,388.61. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Don C. Stark sold 9,900 shares of the company’s stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $2.97, for a total value of $29,403.00. Following the transaction, the director now directly owns 55,848 shares of the company’s stock, valued at $165,868.56. The disclosure for this sale can be found here.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.